New drug cocktail aims to outsmart resistant lung cancer
NCT ID NCT04285671
Summary
This study is testing a combination of three drugs for people with advanced lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to the usual treatment. The goal is to see if adding two antibody drugs (trastuzumab and necitumumab) to the standard pill (osimertinib) is safe and can help control the cancer better. The trial involves about 30 people and will look at side effects, the best dose, and whether the tumors shrink.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.